---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-084735"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:22:02.136035+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Relmada reports Q3 net loss $22.0M; cash $106.3M; REL-1017 Phase 3 enrollment on track

## Summary
- Q3 net loss $22.0M ($0.73/share) vs $39.4M ($1.31) YoY.
- R&D expense $10.5M, down from $30.5M due to Reliance I/III completion.
- Cash and equivalents $106.3M at Sep 30, 2023 vs $148.3M at Dec 31, 2022.
- Phase 3 REL-1017 trials for MDD: Reliance II enrollment on track for H1 2024; Relight for H2 2024.
- Psilocybin program: Phase 1 in steatotic liver disease to start early 2024, Phase 2a planned.

## SEC filing metadata
- accession: 0001213900-23-084735
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/ea187924-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-084735
- JSON: https://secwatch.observer/filing/0001213900-23-084735.json
- Plain text: https://secwatch.observer/filing/0001213900-23-084735.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2023 results: net income Net loss of $22.0 million, EPS $0.73 per basic and diluted share.
  - Period: the three months ended September 30, 2023
  - Net income: Net loss of $22.0 million
  - EPS: $0.73 per basic and diluted share
  - Result: preliminary results
  source text: Net loss for the three months ended September 30, 2023, was $22.0 million, or $0.73 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2023 results: net income Net loss of $73.6 million, EPS $2.45 per share.
  - Period: the nine months ended September 30, 2023
  - Net income: Net loss of $73.6 million
  - EPS: $2.45 per share
  - Result: preliminary results
  source text: Net loss for the nine months ended September 30, 2023 and 2022 was $73.6 million and $119.1 million, respectively. The Company had a net loss of $2.45 and $4.04 per share for the nine months ended September 30, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390023084735/0001213900-23-084735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.